Evidence map›Paper›PMID 20047624›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2010

Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.

Amber L Beitelshees, Yan Gong, Kent R Bailey, Stephen T Turner, Arlene B Chapman, Gary L Schwartz, John G Gums, Eric Boerwinkle, Julie A Johnson

Erratum issued Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00246519 (Pharmacogenomic Evaluation of Antihypertensive Responses), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00246519 phase4completednot on this map

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

TypeinterventionalSponsorUniversity of FloridaRan2005 to 2010Enrolled1,701ConditionsHypertensionArmsHydrochlorothiazide, Atenolol
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Home Blood Pressure Monitoring.European cardiology · 2015
    Review
  5. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Amber L BeitelsheesDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. abeitels@medicine.umaryland.edu
Yan Gong
Kent R Bailey
Stephen T Turner
Arlene B Chapman
Gary L Schwartz
John G Gums
Eric Boerwinkle
Julie A Johnson
Mayo Clinic · USUniversity of Florida · USAmerican Association of Colleges of Pharmacy · USEmory University · USInstitute for Molecular Medicine · USMayo Clinic in Arizona · USUniversity of Maryland, Baltimore · US

Funding

MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
WHITE MATTER AND COGNITION IN PARKINSON'S DISEASEM01RR000082 · NCRR · UNIVERSITY OF FLORIDA · PI BYRNE, BARRY J · 1985 to 2009
$29.7M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-BlockersK23HL091120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BEITELSHEES, AMBER L · 2008 to 2012
$661k
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000454NCRR NIH HHS M01 RR000039NCRR NIH HHS M01 RR000082NCRR NIH HHS M01 RR00039NCRR NIH HHS M01 RR00082NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1 RR025008NHLBI NIH HHS K23 HL091120NHLBI NIH HHS K23HL091120NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

Office, home, and ambulatory blood pressure (BP) demonstrate variable associations with outcomes. The authors sought to compare office BP (OBP), home BP (HBP), and ambulatory BP (ABP) for measuring responses to hydrochlorothiazide (HCTZ), atenolol, and their combination. After completing washout, eligible patients were randomized to atenolol 50 mg or HCTZ 12.5 mg daily. Doses were doubled after 3 weeks and the alternate drug was added after 6 weeks if BP was >120/70 mm Hg (chosen to allow maximum opportunity to assess genetic associations with dual BP therapy in the parent study). OBP (in triplicate), HBP (twice daily for 5 days), and 24-hour ABP were measured at baseline, after monotherapy, and after combination therapy. BP responses were compared between OBP, HBP, and ABP for each monotherapy and combination therapy. In 418 patients, OBP overestimated BP response compared with HBP, with an average 4.6 mm Hg greater reduction in systolic BP (P<.0001) and 2.1 mm Hg greater reduction in diastolic BP (P<.0001) across all therapies. Results were similar for atenolol and HCTZ monotherapy. ABP response was more highly correlated with HBP response (r=0.58) than with OBP response (r=0.47; P=.04). In the context of a randomized clinical trial, the authors have identified significant differences in HBP, OBP, and ABP methods of measuring BP response to atenolol and HCTZ monotherapy.

Indexed as

AdolescentAdultAgedAntihypertensive AgentsAtenololBlood PressureBlood Pressure Monitoring, AmbulatoryDrug Therapy, CombinationFemaleHumansHydrochlorothiazideMaleMiddle AgedTreatment OutcomeAntihypertensive AgentsAtenololHydrochlorothiazide

Identifiers

PMID20047624
PMCPMC2841560
OpenAlexW2098179017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.